ClinicalTrials.gg
CompletedNCT01079663Updated Jun 15, 2021Results posted

The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis

A Phase 2 interventional study of Chlorhexidine 2.5 mg and Placebo chip in Peri-implantitis, sponsored by Dexcel Pharma Technologies Ltd.. Completed at 2 sites in Israel. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by Dexcel Pharma Technologies Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis.

Read the detailed description

This is a Phase 2a study assessing the safety and efficacy of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis

02

Conditions studied

  • Peri-implantitis

Browse trials for

03

In context

Peri-Implantitis

323 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.

This study's enrollment of 60 is above the median of 40 across 195 interventional studies indexed under Peri-Implantitis.

Browse Peri-Implantitis studies →

Lead sponsor

Dexcel Pharma Technologies Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated Form.
  2. Good general health.
  3. Male or female patients aged >21 years old.
  4. Availability for the 25 week duration of the study.
  5. Peri-implantitis is characterized by the presence of at least 1 implant with periodontal pockets of 6-10 mm in depth (potential target implant) demonstrating Bleeding on Probing without involving the apex of the implant and confirmed radiographically.
  6. Females of must be non-pregnant and non-lactating at entry and agree to use an adequate method of during the study.

Exclusion criteria

Exclusion Criteria:

  1. Presence of oral local mechanical factors that could (in the opinion of the Investigator) influence the outcome of the study.
  2. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed.
  3. Presence of soft or hard tissue tumours of the oral cavity.
  4. Horizontal inter implant distance ≤2 mm (if an adjacent implant exists).
  5. Selection of the following dental implant types as target implant/s: hydroxylapatite (HA) and/or Titanium Plasma-sprayed (TPS).
  6. History of allergy to Chlorhexidine.
  7. Patients treated with systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
  8. Patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration (excluding treatment of acetylsalicylic acid ≤100 mg /day).
  9. Patients taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
  10. Presence of any of the following conditions: Type 1 diabetes, major recurrent aphtae stomatitis, abscesses and related oral pathologies.
  11. The presence of any medical or psychiatric condition or any other condition that, in the opinion of the Investigator, could affect the successful participation of the patient in the study.
  12. Patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
  13. Patient uses Chlorhexidine oral rinses/ mouthwashes on a regular basis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Chlorhexidine chip (Periochip®)

    PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm

    Drug: Chlorhexidine 2.5 mg

  • Placebo comparator
    Placebo chip

    Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm

    Drug: Placebo chip

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket

    Pocket depth is the measurement of the distance from the coronal edge of the gingival margin to the base of the pocket. Measurements were taken with a standard 15-mm University of North Carolina (UNC) periodontal probe. Change from baseline in PPD was calculated as Week 24 PPD minus Baseline PPD such that a negative difference indicates an improvement in condition

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Clinical Attachment Levels (CAL)

    Loss of attachment is defined as the distance in millimetres that the base of the pocket has migrated apically from the gingival margin of the crown. CAL was calculated at the same site that PPD was measured

    Time frame: Baseline to Week 24

  2. Bleeding on Probing (BOP)

    BOP was measured at the same site after measuring the PPD. The scoring system used for recording the BOP was a dichotomous one: 0 = No bleeding 1 = Bleeding on probing of the pocket base

    Time frame: Baseline to Week 24

07

Results

Posted Jun 15, 2021

Participant flow

Participant flow — Overall Study
MilestoneChlorhexidine Chip (Periochip®)Placebo Chip
Started3030
Completed3026
Not completed04
Withdrew: Adverse event02
Withdrew: Protocol violation02

Outcome measures

PrimaryChange in Mean Probing Pocket Depth (PPD) for Selected Target Pocket

Pocket depth is the measurement of the distance from the coronal edge of the gingival margin to the base of the pocket. Measurements were taken with a standard 15-mm University of North Carolina (UNC) periodontal probe. Change from baseline in PPD was calculated as Week 24 PPD minus Baseline PPD such that a negative difference indicates an improvement in condition

Time frame:
Baseline to Week 24
Reported as:
Mean · mm
Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket
mmChlorhexidine Chip (Periochip®)Placebo Chip
Change in Mean Probing Pocket Depth (PPD) for Selected Target Pocket-2.13 ± 1.399-1.79 ± 1.149
Statistical analysis
  • Chlorhexidine Chip (Periochip®) vs Placebo Chip · Mixed Models Analysis · p = 0.1629 · Mean difference (final values): -0.49 · 95% CI -1.19 to 0.20
SecondaryClinical Attachment Levels (CAL)

Loss of attachment is defined as the distance in millimetres that the base of the pocket has migrated apically from the gingival margin of the crown. CAL was calculated at the same site that PPD was measured

Time frame:
Baseline to Week 24
Reported as:
Mean · mm
Clinical Attachment Levels (CAL)
mmChlorhexidine Chip (Periochip®)Placebo Chip
Clinical Attachment Levels (CAL)-2.18 ± 1.394-1.76 ± 1.257
Statistical analysis
  • Chlorhexidine Chip (Periochip®) vs Placebo Chip · Mixed Models Analysis · p = 0.0347 · Mean difference (final values): -0.76 · 95% CI -1.46 to -0.06
SecondaryBleeding on Probing (BOP)

BOP was measured at the same site after measuring the PPD. The scoring system used for recording the BOP was a dichotomous one: 0 = No bleeding 1 = Bleeding on probing of the pocket base

Time frame:
Baseline to Week 24
Reported as:
Count of units · Target implant
Bleeding on Probing (BOP)
Target implantChlorhexidine Chip (Periochip®)Placebo Chip
Bleeding on Probing (BOP)2316

Adverse events

Collected over Baseline through Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chlorhexidine Chip (Periochip®)0/30 (0%)0/30 (0%)15/30 (50%)
Placebo Chip0/30 (0%)2/30 (6.7%)16/30 (53.3%)
Most frequent serious events
Most frequent serious events
EventChlorhexidine Chip (Periochip®)Placebo Chip
Head injuryInjury, poisoning and procedural complications0/301/30
OsteoarthritisMusculoskeletal and connective tissue disorders0/301/30
Most frequent other events
Most frequent other events
EventChlorhexidine Chip (Periochip®)Placebo Chip
Implant site painGeneral disorders2/304/30
Gingival swellingGastrointestinal disorders3/300/30
Periodontal diseaseGastrointestinal disorders3/300/30
Periodontal inflammationGastrointestinal disorders0/303/30
Feeling coldGeneral disorders3/301/30
Aphthous ulcerGastrointestinal disorders1/302/30
ToothacheGastrointestinal disorders0/302/30
NasopharyngitisInfections and infestations2/300/30
Dental restoration failureInjury, poisoning and procedural complications0/302/30
Tooth extractionSurgical and medical procedures1/302/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Chlorhexidine Chip (Periochip®)Placebo ChipTotal
Mean56.7 ± 10.5160.1 ± 7.8858.4 ± 9.38
Sex: Female, Male
Sex: Female, Male(Participants)Chlorhexidine Chip (Periochip®)Placebo ChipTotal
Female201535
Male101525
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Chlorhexidine Chip (Periochip®)Placebo ChipTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White303060
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Chlorhexidine Chip (Periochip®)Placebo ChipTotal
Israel303060
08

Study locations

2 sites
  • Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center
    Haifa, Israel
  • The Oral & Maxillofacial Surgery Unit of the Tel Aviv Medical Center
    Tel Aviv, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2021, 9 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 3, 2010
Start
Mar 2010
Primary completionActual
Oct 2011
CompletionActual
Nov 2011
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01079663
Lead sponsor
Dexcel Pharma Technologies Ltd.
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
Mar 2010
Primary completion
Oct 2011
Completion
Nov 2011
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine

Start the discussion